Clinical trials: HR+ Metastatic Breast Cancer

Breast Cancer

A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

• Completed
• Age: All ages
• Observational study
• Results posted

The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.

Trial name

NCT06307457

Testing

Palbociclib in combination with AI

Where

Denmark

Volunteers

604 people

Sponsor

Pfizer